Skip to content
OpenCapital
Get started

OS Therapies OSTX R&D credit carryforward

R&D credit carryforward at other companies

CTO
Citius Oncology, Inc.CTOR
$1.58M+52.8%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: OS Therapies’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's r&d credit carryforward?
OS Therapies (OSTX) reported r&d credit carryforward of $268.57K in Q4 2025.
What is the long-term trend for OS Therapies's r&d credit carryforward?
Over 2 years (2023 to 2025), OS Therapies's r&d credit carryforward has grown at a 0.0% compound annual growth rate (CAGR), from $268.57K to $268.57K.
What does r&d credit carryforward mean?
This reflects the value of accumulated research and development tax credits that can be applied to offset future taxable income. It is a significant asset for clinical-stage companies, representing potential future tax savings as the company moves toward commercialization.